A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.


Updates from The Motley Fool

Latest updates on Cytokinetics from Fool.com.
This Week in Biotech

With the  SPDR S&P Biotech Index  up 38% over the trailing-12-month period, it's evident that inv...

5 Reasons Not to Worry This Week

It's not a perfect world out there for investors, but things may be starting to get better. I rec...

These Underdogs Are No Dogs

Short-sellers and hedge funds may be shadowy, but sometimes they are the smartest guys in the roo...

3 Top Stocks at Half-Price

You love buying your shirts when they go on sale. And who can resist a buy-one-get-one-free offer...

3 Stocks Ready to Roar

There are plenty of strategies for picking stock winners, from finding low P/E stocks to seeking ...



Stock Performance

View Interactive CYTK Charts
Sponsored by

Key Data Points

Primary metrics and data points about Cytokinetics.
Current Price: $11.20
Prev Close: $11.25
Open: $11.25
Bid: $11.15
Ask: $11.20
Day's Range: $10.87 - $11.28
52wk Range: $6.00 - $12.98
Volume: 42,241
Avg Vol 332,964
Market Cap: $435M
P/E (ttm): -225.00
EPS (ttm): ($0.05)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Cytokinetics.
CAPS Rating 2 out of 5
 
163 Outperform
20 Underperform
CAPS All Stars
 
34 Outperform
5 Underperform

How do you think Cytokinetics will perform against the market?



You pick for Cytokinetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Robert I. Blum, CEO

64% Approve

Based on 5 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Cytokinetics.

A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers